Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Dermatology

Free Subscription Articles published in Lancet Retrieve available abstracts of 73 articles: HTML format

Single Articles

August 2026
1. SILVERBERG JI, Rosmarin D, Bieber T, Chovatiya R, et al
   Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
   Lancet. 2026 Aug 21:S0140-6736(26)01143-8. doi: 10.1016/S0140-6736(26)01143.
   PubMed     Abstract available
   
   
   
2. VALENZUELA F, Munoz MD
   Expanding regulatory T cells to treat atopic dermatitis.
   Lancet. 2026 Aug 21:S0140-6736(26)01242-0. doi: 10.1016/S0140-6736(26)01242.
   PubMed    
   
   
   
3. PASSERON T, Prajapati VH, Sivamani RK, Ezzedine K, et al
   Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.
   Lancet. 2026;408:636-648.
   PubMed     Abstract available
   
   
   
4. THE LANCET
   Skin diseases: beyond the visible.
   Lancet. 2026;408:577.
   PubMed    
   
   
   July 2026
5. EDER L, Perez-Chada L, Liao W, Merola JF, et al
   Psoriasis.
   Lancet. 2026 Jul 29:S0140-6736(26)00349-1. doi: 10.1016/S0140-6736(26)00349.
   PubMed     Abstract available
   
   
   May 2026
6. 
   Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials.
   Lancet. 2026;407:1699-1711.
   PubMed     Abstract available
   
   
   April 2026
7. GUPTA K, Ghebrial M, Tognaccini C, Ghanim D, et al
   Rocatinlimab atopic dermatitis in two global phase 3 clinical trials.
   Lancet. 2026;407:1509-1510.
   PubMed    
   
   
   March 2026
8. RIVERA S, Ghodssighassemabadi R, Auzac G, Brion T, et al
   5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.
   Lancet. 2026;407:976-987.
   PubMed     Abstract available
   
   
   February 2026
9. XIAO Y, Mar V, Amani A, Parajuli N, et al
   The Lancet Commission on Skin Health: aligning with WHO priorities.
   Lancet. 2026 Feb 26:S0140-6736(26)00365-X. doi: 10.1016/S0140-6736(26)00365.
   PubMed    
   
   
   
10. HARADA-SHOJI N, Suzuki A, Ishida T, Yamamoto S, et al
    Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.
    Lancet. 2026;407:784-793.
    PubMed     Abstract available
    
    
    
11. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
    VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
    Lancet. 2026;407:637-648.
    PubMed     Abstract available
    
    
    January 2026
12. GOMMERS J, Hernstrom V, Josefsson V, Sartor H, et al
    Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy tria
    Lancet. 2026;407:505-514.
    PubMed     Abstract available
    
    
    November 2025
13. GUTTMAN-YASSKY E, Kabashima K, Worm M, Luna PC, et al
    Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
    Lancet. 2025 Nov 25:S0140-6736(25)01865-3. doi: 10.1016/S0140-6736(25)01865.
    PubMed     Abstract available
    
    
    
14. ATASH K, Boesjes CM, de Bruin-Weller MS
    Targeting OX40: rocatinlimab-a novel therapy for atopic dermatitis.
    Lancet. 2025 Nov 25:S0140-6736(25)02152-X. doi: 10.1016/S0140-6736(25)02152.
    PubMed    
    
    
    October 2025
15. CACOUB P, Vieira M, Langford CA, Tazi Mezalek Z, et al
    Large-vessel vasculitis.
    Lancet. 2025;406:2017-2032.
    PubMed     Abstract available
    
    
    
16. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
    Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
    Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
    PubMed     Abstract available
    
    
    September 2025
17. GOLD LS, Armstrong AW, Bissonnette R, Magnolo N, et al
    Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
    Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576.
    PubMed     Abstract available
    
    
    
18. PUIG L
    Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy.
    Lancet. 2025 Sep 18:S0140-6736(25)01675-7. doi: 10.1016/S0140-6736(25)01675.
    PubMed    
    
    
    August 2025
19. 
    Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    PubMed     Abstract available
    
    
    
20. BRAIN E, Mir O, Bourbouloux E, Rigal O, et al
    Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
    Lancet. 2025;406:489-500.
    PubMed     Abstract available
    
    
    July 2025
21. TANG JY, Marinkovich MP, Wiss K, McCarthy D, et al
    Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
    Lancet. 2025;406:163-173.
    PubMed     Abstract available
    
    
    June 2025
22. EBENS CL
    Targeting challenging RDEB skin wounds with gene therapy.
    Lancet. 2025 Jun 23:S0140-6736(25)01154-7. doi: 10.1016/S0140-6736(25)01154.
    PubMed    
    
    
    May 2025
23. GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al
    Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
    Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582.
    PubMed     Abstract available
    
    
    
24. GIMENEZ-ARNAU AM, Pinter A, Sondermann W, Reguiai Z, et al
    Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
    Lancet. 2025;405:1676-1688.
    PubMed     Abstract available
    
    
    February 2025
25. GUTTMAN-YASSKY E, Renert-Yuval Y, Brunner PM
    Atopic dermatitis.
    Lancet. 2025;405:583-596.
    PubMed     Abstract available
    
    
    
26. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    PubMed     Abstract available
    
    
    
27. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    PubMed     Abstract available
    
    
    January 2025
28. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    PubMed     Abstract available
    
    
    December 2024
29. WEIDINGER S, Novak N
    Hand eczema.
    Lancet. 2024;404:2476-2486.
    PubMed     Abstract available
    
    
    November 2024
30. CHONG DHY, Pasternak S, Taylor T, Armstrong S, et al
    Skin biopsy findings of dyskeratotic keratinocytes and vacuolar interface change in a patient with Still's disease.
    Lancet. 2024;404:e6.
    PubMed    
    
    
    
31. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    PubMed     Abstract available
    
    
    October 2024
32. JAIRATH V, Acosta Felquer ML, Jaihyun Cho R
    IL-23 inhibition for chronic inflammatory disease.
    Lancet. 2024;404:1679-1692.
    PubMed     Abstract available
    
    
    
33. 
    Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
    Lancet. 2024;404:1407-1418.
    PubMed     Abstract available
    
    
    
34. TARANTINO P, Tolaney SM
    Progress in breast cancer management.
    Lancet. 2024;404:1376-1378.
    PubMed    
    
    
    September 2024
35. NARAGHI K, Marzo-Ortega H
    Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea.
    Lancet. 2024;404:e4.
    PubMed    
    
    
    August 2024
36. LEBWOHL MG, Thoma C, Haeufel T
    Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lancet. 2024;404:847-848.
    PubMed    
    
    
    
37. OSBORNE S, Thacker S, Kam O, Wescott R, et al
    Spesolimab use in generalised pustular psoriasis flares.
    Lancet. 2024;404:846-847.
    PubMed    
    
    
    
38. MANN GB, Rose AK, Zdenkowski N
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
    Lancet. 2024;404:526.
    PubMed    
    
    
    
39. KUNKLER I, Cameron D, Dixon M, Williams L, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525.
    PubMed    
    
    
    
40. SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525-526.
    PubMed    
    
    
    
41. MO DC, Huang JF, Luo PH, Wang HL, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:524-525.
    PubMed    
    
    
    
42. RENERT-YUVAL Y, Guttman-Yassky E
    Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
    Lancet. 2024;404:409-411.
    PubMed    
    
    
    July 2024
43. RUGO HS, Bardia A, Tolaney S
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
    Lancet. 2024;404:339-340.
    PubMed    
    
    
    
44. HARADA K, Ozaki A, Tanimoto T
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:339.
    PubMed    
    
    
    
45. MESSORI A
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338-339.
    PubMed    
    
    
    
46. GU Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338.
    PubMed    
    
    
    
47. ERGUN Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:337-338.
    PubMed    
    
    
    
48. ZUBERBIER T, Ensina LF, Gimenez-Arnau A, Grattan C, et al
    Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment.
    Lancet. 2024;404:393-404.
    PubMed     Abstract available
    
    
    
49. BRUNNER PM
    A novel treatment approach for atopic dermatitis.
    Lancet. 2024 Jul 25:S0140-6736(24)01488-0. doi: 10.1016/S0140-6736(24)01488.
    PubMed    
    
    
    
50. SILVERBERG JI, Wollenberg A, Reich A, Thaci D, et al
    Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Lancet. 2024 Jul 24:S0140-6736(24)01203-0. doi: 10.1016/S0140-6736(24)01203.
    PubMed     Abstract available
    
    
    
51. BISSONNETTE R, Warren RB, Pinter A, Agner T, et al
    Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
    Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027.
    PubMed     Abstract available
    
    
    June 2024
52. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    PubMed     Abstract available
    
    
    
53. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    PubMed    
    
    
    May 2024
54. BHUTTA MF, Leach AJ, Brennan-Jones CG
    Chronic suppurative otitis media.
    Lancet. 2024;403:2339-2348.
    PubMed     Abstract available
    
    
    
55. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed     Abstract available
    
    
    
56. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    PubMed    
    
    
    
57. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.
    PubMed    
    
    
    
58. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.
    PubMed    
    
    
    
59. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.
    PubMed    
    
    
    
60. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.
    PubMed    
    
    
    
61. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.
    PubMed    
    
    
    
62. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.
    PubMed    
    
    
    April 2024
63. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    PubMed    
    
    
    
64. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    PubMed    
    
    
    
65. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    PubMed    
    
    
    
66. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    PubMed    
    
    
    
67. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    PubMed    
    
    
    
68. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    PubMed     Abstract available
    
    
    March 2024
69. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    PubMed    
    
    
    
70. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    PubMed    
    
    
    
71. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available
    
    
    
72. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available
    
    
    February 2024
73. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum